End of 12-Year R&D Leadership and Planned Management Succession

Andy Plump, President of R&D at Takeda Pharmaceutical who has led the research and development organization for 12 years, has announced his official retirement and begun the process of leadership succession. Dr. Plump, who joined Merck & Co. and Sanofi before joining in 2015, is expected to fully support the successor handover and global approval schedule as a board member and head of R&D until the regular shareholders' meeting in June 2027. This retirement announcement is widely analyzed as a strategic generational transition implemented immediately after breaking through the large-scale patent cliff crisis faced by Takenaga with new pipelines, going beyond mere executive replacement. In the global big pharma environment for new drug R&D, which has a long cycle, the decision to provide a sufficient succession grace period of more than one year is interpreted as an intention to protect regulatory agency responses and continuity of late-stage clinical trial tasks.

Responding to Patent Expirations of Vyvanse and Entyvio and Achieving Commercialization Success

Takeda has experienced severe sales declines due to the entry of generic drugs following the loss of exclusivity (LOE) for its flagship product, Vyvanse (generic name lisdexamfetamine), a treatment for attention deficit hyperactivity disorder (ADHD). Here, Entyvio (generic name: vedolizumab), a flagship antibody therapy for inflammatory bowel disease (IBD) that generates over $5 billion in annual sales, is also approaching patent expiration, making it urgent to secure alternative growth drivers. Dr. Flump has recently built a defensive wall by securing consecutive approvals from the U.S. Food and Drug Administration (FDA) for Orzeyful (development code name TAK-861), the first oral orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1, and Mimrylo (generic name rusfertide), a treatment for Polycythemia Vera. Furthermore, the successful commercialization of the cytomegalovirus (CMV) inhibitor Livtencity and the new drug for thrombotic thrombocytopenic purpura (cTTP), Adzynma, has laid the groundwork to fill the sales gap.

$6 Billion Commercialization of Zasocitinib and Blockbuster Competition

In particular, zasocitinib (development code TAK-279), an oral TYK2 inhibitor and a core pillar of Takeda's next-generation pipeline, has secured positive topline results in Phase 3 clinical trials for moderate-to-severe plaque psoriasis. Takeda declared its intent to reclaim leadership in the autoimmune disease market by acquiring this asset from Nimbus Therapeutics for a total of $6 billion, including a $400 million upfront payment and up to $2 billion in commercialization milestones in 2023. Zasocitinib is targeting the multi-billion-dollar autoimmune disease market by leveraging superior allosteric selectivity compared to Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib), which currently dominates the market. The next R&D head will face the heavy responsibility of smoothly completing the global regulatory filing (NDA/MAA) processes and successfully conducting clinical trials for follow-up indications such as Psoriatic Arthritis (PsA) and IBD.

Lessons from Cell Therapy Withdrawal and Portfolio Reorganization Focused on Selection and Concentration

It is also a point that the market is watching coldly, noting that not all research and development projects during Dr. Flump's tenure went smoothly. Takeda has not achieved the expected results in its investments in the cell therapy field, including the acquisition of GammaDelta Therapeutics, and officially withdrew from that modality last year, recognizing a significant impairment loss. Furthermore, Alofisel (generic name darvadstrocel), a Crohn's disease fistula stem cell therapy acquired through the acquisition of TiGenix for €520 million, was voluntarily withdrawn from the European market after failing to demonstrate efficacy in its pivotal Phase 3 clinical trials. Next-generation R&D leadership is expected to continue an efficiency strategy that focuses R&D budgets on low-molecular-weight compounds and validated targets, using the trial-and-error of this high-cost, low-yield modality as a cautionary tale.